AI Drug Discovery Funding Outpaces Clinical Results: Only One Pipeline at Phase III

量子位 · wechat · 2026-09-19

A QbitAI analysis of AI drug discovery players' routes, funding, pipelines and pharma deals arrives at five conclusions:

Routes diverge: XtalPi, Schrödinger and Isomorphic lean toward platforms and computational design; Insilico Medicine and Huashen focus on proprietary pipelines; Recursion spans data platforms, clinical assets and partnerships.
Capital doesn't track clinical progress: Isomorphic leads with $2.7B in disclosed external funding but has no named clinical candidate, while Insilico's Rentosertib is already in Phase III.
Pipelines are top-heavy: most AI-involved candidates sit at Phase I, only 3 at Phase II, and Rentosertib is the sole Phase III asset with no approved product; Huashen's HXN-1001 entered Phase IIa.
Pharma buys both tech and assets: upfront payments up to $150M (Recursion, Schrödinger) reflect real commercial value better than headline deal caps.
Next 24 months = clinical validation window, hinging on Rentosertib Phase III, Intismeran filing, HXN-1001 IIa data, and revenue durability.

More from Venture